One Week, Not a Relapse: Holding a GLP-1 Before Elective Surgery Without Losing a Year of Progress
A patient a year into meaningful weight loss on semaglutide faces a recommended preoperative hold for an elective procedure — and genuine fear that any interruption will undo his progress the way sustained discontinuation has been shown to.
Desmond K., a 52-year-old warehouse supervisor, is scheduled for an elective laparoscopic cholecystectomy next month, and spent more of his preoperative visit talking about his semaglutide than about the surgery itself. He's lost 22% of his body weight over the past year — down from a BMI of 38 to 29.6 — and described, without prompting, watching a coworker regain most of a comparable loss after a monthslong pause in his own GLP-1 therapy following a job loss and lapse in insurance coverage. That story is clearly doing a lot of work in how Desmond is bracing for this conversation before it's even started; he brought it up twice more before the surgical consent form had even been signed.
The actual clinical question in front of the team is narrower than what Desmond is anticipating, but not imaginary: current anesthesiology consensus guidance recommends holding weekly GLP-1 receptor agonists for a full dosing interval before procedures involving sedation or general anesthesia, out of concern that delayed gastric emptying — the same mechanism that drives the drug's appetite-suppressing effect — can leave retained gastric contents behind even after a standard preoperative fasting period, raising aspiration risk during induction. Desmond reports no nausea, no early satiety, and no reflux at all on his current dose, which is reassuring about his day-to-day tolerance and close to irrelevant here — delayed emptying has been demonstrated on imaging in patients with no symptoms whatsoever, so an untroubled stomach on a Tuesday says very little about what is still sitting in it on an operating table. That guidance is real and worth following; whether it requires the kind of sustained interruption Desmond watched derail his coworker's progress is the part of the conversation that needs untangling before his surgery date arrives.
In preoperative clinic, a hold and a fear of losing ground
I'd hold his semaglutide per the current ASA consensus guidance — a full weekly dosing interval before an elective procedure under sedation or general anesthesia, given the real, mechanism-based concern about delayed gastric emptying and retained gastric contents raising aspiration risk. This isn't a theoretical worry; there are published case reports of aspiration events in patients on GLP-1 therapy undergoing sedation who hadn't held the drug.
I want to be honest about the evidence base here too: this guidance is consensus-based, drawing on case reports and pharmacologic reasoning about gastric emptying rather than a large randomized trial specifically testing hold-versus-continue outcomes. It's the right default given what we know, not a settled, high-certainty finding.
I don't dispute the aspiration mechanism, but I want to raise what a full week off does to a patient like him specifically. He's lost 22% of his body weight over the past year and has told me directly that he's frightened of any interruption undoing that progress — not an irrational fear given what we know about post-discontinuation regain, even over a much shorter interval than a full month of missed doses around a surgical episode.
A week-long hold for one procedure is very different from the sustained discontinuation the regain data actually describes, and I think that distinction is worth making explicit to him rather than letting his anxiety generalize past what the actual interruption represents.
That's a fair distinction and I'd make it to him directly. I'd also offer a concrete mitigation that doesn't require abandoning the hold: a preoperative liquid diet the day before the procedure, and if there's any clinical doubt about gastric emptying at the time of the procedure, a point-of-care gastric ultrasound before induction to actually check rather than assume. That converts a blanket rule into a verified individual assessment for a patient who has real reasons to want the hold minimized rather than automatic.
Agreed: hold one weekly dose of semaglutide before the procedure, add a 24-hour preoperative liquid diet, and perform a point-of-care gastric ultrasound before induction if any clinical doubt remains about residual gastric content — converting a blanket rule into a verified, individualized decision. Desmond was told explicitly that a single missed weekly dose is a very different exposure than the sustained, months-long gap his coworker experienced.
Not fully settled: exactly how anesthesiology teams elsewhere should weigh the guidance's own acknowledged evidence limits against the real, if currently uncommon, aspiration case reports driving it, as more perioperative outcomes data on GLP-1 patients accumulates. That broader question was noted as unresolved in the literature generally, distinct from the specific, resolved plan made for Desmond's own procedure.